| Roos YBWEM et al, 2003, Netherlands | 9 trials involving 1399 patients included. Papers sourced through electronic and hand searching methods. RCTs of IV or oral agents included. Only confirmed SAH patients. | Systematic review and Meta analysis | Poor outcome (defined as death, vegetative state or severe disability) | Non significant. OR of 1.12 (CI 0.88–1.43) for poor outcome with treatment | This is a well researched review. The studies match the clinical problem well. Of 21 trials found only 9 satisfied the quality filter of the authors which suggests some rigour in the approach used). One of the review authors’ own study was included in the review. |
| | | Rebleeding at end of follow up | Less with treatment OR = 0.55 (CI 0.42–0.71) | |
| | | Risk of cerebral ischaemia | Worse with treatment OR = 1.39 (CI 1.07–1.82) | |
| | | Risk of death | Non significant. OR = 0.99 (CI 0.79–1.24) | |
| | | Rate of hydrocephalus | Non significant. OR = 1.14 (CI 0.86–1.51) | |